Shopping Cart
- Remove All
Your shopping cart is currently empty
MI-3454
🥰Excellent
Catalog No. T39584Cas No. 2134169-43-8
MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.MI-3454 induces complete remission or regression of leukemia in a mouse model of leukemia with MLL1 rearrangement or NPM1 mutation through the down-regulation of key genes involved in leukemogenesis. complete remission or remission.
MI-3454
🥰Excellent
Purity: 99.68%
Catalog No. T39584Cas No. 2134169-43-8
MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.MI-3454 induces complete remission or regression of leukemia in a mouse model of leukemia with MLL1 rearrangement or NPM1 mutation through the down-regulation of key genes involved in leukemogenesis. complete remission or remission.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $198 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "MI-3454"
MAK-683 hydrochloride
T96812170606-94-5In house
MAK683 hydrochloride embryonic ectodermal development (EED) inhibitor, also a potent PRC2 inhibitor, blocked cancer cell proliferation (IC50=1.014nM), with IC50 values of 59, 26, and 89 nM measured in EED Alphascreen, ELISA, and LC-MS assays, respectively.
- $195
Size
QTY
EPZ015666
GSK3235025
T60761616391-65-1
EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymatic activity.
- $42
Size
QTY
MRTX-1719
T402542630904-45-7
MRTX-1719 is a potent and selective inhibitor of the PRMT5/MTA complex with an IC50 value of <10 nM against PRMT5/MTAMTAPDELSDMA cell lines.
- $398
Size
QTY
Tazemetostat
Cited
EPZ6438, E-7438
T17881403254-99-8
Tazemetostat (EPZ6438) is a histone methyltransferase EZH2 inhibitor (IC50=11 nM) that is orally active, selective, and SAM-competitive. Tazemetostat exhibits antitumor activity and may be used for the treatment of epithelioid sarcoma/follicular lymphoma.
- $59
Size
QTY
CitedPiribedil
Trivastan, Trivastal, EU-4200, ET-495
T32783605-01-4
Piribedil (Trivastan) is a dopamine D2 agonist, used in the treatment of Parkinson's disease.
- $52
Size
QTY
iso-Azalansta
Iso-RS-21607（Iso-143393-27-5）, Iso-RS-21607, Iso-Azalansta
T25127L143393-29-7
(2R,4S)-Azalanstat (Iso-Azalansta) is a selective heme oxygenase (HO) inhibitor that is used in the study of cardiovascular disease.
- $195
Size
QTY
MAK683
T152011951408-58-4In house
MAK683 is an inhibitor of embryonic ectoderm development (EED) (IC50s: 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay).
- $48
Size
QTY
XY1
T71571624117-53-8
XY1 is a close analogue of SGC707 (a potent, selective, and non-competitive inhibitor of PRMT3 with IC50 of 31 nM), intended as a negative control for SGC707 in studies involving PRMT3 action.
- $31
Size
QTY
ORIC-944
ORIC944
T870732369769-29-7
ORIC-944 is an orally available and selective variant of PRC2 with anticancer activity for prostate cancer research.
- $75
Size
QTY
AMI-1 free acid
T22239134-47-4
AMI-1 free acid is a potent, cell-permeable, and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with inhibitory concentration 50 (IC50) values of 8.8 μM for human PRMT1 and 3.0 μM for yeast-Hmt1p. It achieves its PRMTs inhibitory activity by obstructing peptide-substrate binding [1].
- $40
Size
QTY
MS37452
T21767423748-02-1
MS37452 is a competitive inhibitor of CBX7 chromodomain binding to H3K27me3 (Ki = 43 µM).
- $47
Size
QTY
BIX-01294 trihydrochloride Cited
BIX 01294
T19591392399-03-9
BIX-01294 trihydrochloride is an inhibitor of G9a histone methyltransferase.In a cell-free assay, the IC50=2.7 μM for G9a histone methyltransferase.
- $37
Size
QTY
CitedSelect Batch
Purity:99.68%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.MI-3454 induces complete remission or regression of leukemia in a mouse model of leukemia with MLL1 rearrangement or NPM1 mutation through the down-regulation of key genes involved in leukemogenesis. complete remission or remission. |
| Targets&IC50 | Menin-MLL1:0.51 nM |
| In vitro | In murine bone marrow cells transformed with MLL-AF9 or Hoxa9/Meis1, MI-3454 (0.001, 0.01, 0.1, 1, 10 μM; 7 days) demonstrated a significant reduction in cell proliferation[1]. |
| In vivo | In 8- to 10-week-old female NSG mice (MV-4-11 xenotransplantation model of MLL leukemia), MI-3454 (120 mg/kg; orally; once or twice daily for 7 consecutive days) is sufficient to block leukemia progression[1]. |
| Molecular Weight | 636.73 |
| Formula | C32H35F3N8OS |
| Cas No. | 2134169-43-8 |
| Smiles | CNc1nc(NC2CCN(Cc3ccc4n(CC56CC(C5)(C6)NC=O)c(cc4c3C)C#N)CC2)c2cc(CC(F)(F)F)sc2n1 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | store at low temperature,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (31.41 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy MI-3454 | purchase MI-3454 | MI-3454 cost | order MI-3454 | MI-3454 chemical structure | MI-3454 in vivo | MI-3454 in vitro | MI-3454 formula | MI-3454 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.